Enveric Biosciences (ENVB) News Today → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free ENVB Stock Alerts $0.93 +0.04 (+4.47%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEnveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growthbenzinga.com - March 27 at 10:08 AMEnveric Biosciences Inc (ENVB)uk.investing.com - March 21 at 7:32 PMWhy Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?msn.com - March 19 at 3:26 PMEnveric gains on out-licensing deal of new chemical entities for joint disease treatmentsmsn.com - March 19 at 10:25 AMEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Diseasefinance.yahoo.com - March 19 at 10:25 AMEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheetsfinance.yahoo.com - March 12 at 10:44 AMPsyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And Moremsn.com - March 4 at 6:09 PMWhy Is Enveric Biosciences (ENVB) Stock Up 120% Today?investorplace.com - February 29 at 2:04 PMEnveric Signs Term Sheets To Pursue Out-licensing Of Three Classes Of Compoundsmarkets.businessinsider.com - February 29 at 9:43 AMEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compoundsbusinesswire.com - February 29 at 7:00 AMCORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)finance.yahoo.com - February 26 at 12:50 PMEnveric Biosciences To Sell Cannabinoid-Related Cancer Intellectual Property; Stock Up In Pre-Marketmarkets.businessinsider.com - February 23 at 10:36 AMEnveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Propertybusinesswire.com - February 23 at 8:00 AMEnveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compoundsmsn.com - February 21 at 12:54 PMEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disordersfinance.yahoo.com - February 21 at 12:54 PMEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disordersbusinesswire.com - February 21 at 8:00 AMPsychedelic stocks gain after FDA priority review for MDMA therapymsn.com - February 12 at 1:21 PMEnveric Biosciences Granted Extension to Avoid Nasdaq Delistingmsn.com - February 10 at 7:18 AMEnveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Seriesfinance.yahoo.com - January 3 at 8:52 AMEnveric stock jumps 13% on pipeline updatemsn.com - December 28 at 1:43 PMEnveric Biosciences Shares Rise 7% After Selecting Lead Drug Candidatemarketwatch.com - December 28 at 8:43 AMEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Seriesfinance.yahoo.com - December 28 at 8:43 AMEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373finance.yahoo.com - December 27 at 9:01 AMBears are Losing Control Over Enveric Biosciences, Inc. (ENVB), Here's Why It's a 'Buy' Nowfinance.yahoo.com - December 20 at 1:14 PM5 Biotech stocks tapping into unmet mental health treatment needs (ENVB)marketbeat.com - December 20 at 9:01 AMEnveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"finance.yahoo.com - December 20 at 8:13 AMEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compoundsfinance.yahoo.com - December 5 at 8:54 AMEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivativesfinance.yahoo.com - November 29 at 1:04 PMEnveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)finance.yahoo.com - November 24 at 9:49 AMEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial Resultsfinance.yahoo.com - November 13 at 5:59 PMEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocinfinance.yahoo.com - October 31 at 10:24 AMEnveric Biosciences to Present at the Centurion One 5th Global Summitfinance.yahoo.com - October 20 at 9:26 AMEnveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disordersfinance.yahoo.com - October 18 at 9:07 AMEnveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summitfinance.yahoo.com - October 11 at 10:15 AMEnveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistryfinance.yahoo.com - September 27 at 12:49 PMEnveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Herebenzinga.com - September 21 at 12:23 AMEnveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidatesfinance.yahoo.com - September 20 at 9:21 AMEnveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivativesfinance.yahoo.com - September 11 at 7:21 PMEnveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivativesfinance.yahoo.com - September 5 at 8:57 AMEnveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conferencefinance.yahoo.com - August 30 at 9:32 AMPsyched: Psilocybin For Gambling Addiction, Ex-NHL's Retreat, Fellini's LSD Creativity, Surveys, Financings & Morebenzinga.com - August 28 at 9:26 PMEnveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugsfinance.yahoo.com - August 28 at 11:24 AMDiamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)finance.yahoo.com - August 24 at 8:15 AMEnveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Programbenzinga.com - August 21 at 4:51 PMEnveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Programfinance.yahoo.com - August 21 at 4:51 PMEnveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024benzinga.com - August 14 at 4:38 PMEnveric Biosciences Reports Second Quarter 2023 Corporate and Financial Resultsfinance.yahoo.com - August 14 at 9:05 AMEnveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373finance.yahoo.com - July 24 at 8:40 AMEnveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxietymsn.com - July 17 at 2:44 PMEnveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373finance.yahoo.com - July 17 at 9:43 AM Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address The only accurate crypto trading system I know … (Ad)Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money. Here's what our expert says you should buy before April 14. ENVB Media Mentions By Week ENVB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENVB News Sentiment▼1.000.44▲Average Medical News Sentiment ENVB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENVB Articles This Week▼01▲ENVB Articles Average Week Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SHPH News KZIA News FWBI News AIMD News CVKD News ADIL News PTIX News TENX News VCNX News CLVR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENVB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
